Back to list

Giuseppe Giardina

Research Manager
Industrial Liaison


Technology Transfer Directorate

Industrial Liaison


Via Morego 30
+39 010 2896 258
Contact Me


In May 2014 Giuseppe joined the IIT TTO group, after almost a couple of years within the IIT Drug Discovery & Development (D3) Unit. Key activities in his current role are:
- Market analysis of IIT technologies within the Life Sciences/Pharma sector; branding the most advanced and mature projects within the scientific & business communities to identify and exploit potential partnership and licensing opportunities for IIT Pharma patent applications & assets; matching internal research projects/compounds with market demand and funding opportunities within the investors’ community.
- Management of IIT patent portfolio in the Pharma sector, by revising the record of inventions coming from scientists, managing technical relationships with external patent attorneys, drafting/reviewing patent applications prior to filing, and defining foreign filing and nationalization strategies based on projects/compounds preclinical development status and licensing opportunities.

Giuseppe spent 30 years in the drug discovery arena of life sciences, being involved in all the relevant aspects of the drug discovery & preclinical development process, from synthetic & medicinal chemistry, biochemical pharmacology and ADMET/DMPK profiling of emerging leads to candidate selection and advanced preclinical development studies.
He managed resources up to 90 people (Zambeletti-Beecham, SmithKline Beecham, GlaxoSmithKline and NiKem Research) and was exposed to various aspects of the value chain in the big pharma & CRO outsourcing industries in a variety of top management roles: science, finance, administration, business development, marketing, institutional & public relations. His main expertise is in medicinal chemistry, patenting strategies and portfolio management of small molecule therapeutics, preclinical profiling up to candidate selection and business development of mature projects through licensing or spin-off deals.
During the last 15 years Giuseppe  developed excellent negotiations skills within Business Development & Licensing areas, greatly contributing  to bring to success the following main deals:

  • NiKem Research foundation as a drug discovery spin-off from GSK Discovery Unit in Milan;
  • In-licensing from GSK of the asset named “ORL-1 receptor antagonist project” and developing it up to “candidate selection” milestone, generating payment by GSK for 1 M€;
  • Brane Discovery Foundation as a spin-off specialty company from NiKem;
  • Selling to Neurotune AG (CH) the “Dimiracetam” project on neuropathic pain;
  • Selling to 3V Biosciences the “V-ATPase inhibitors” project on cancer;
  • Selling drug discovery & development services for revenues close to 10 M€ annually to about a hundred of big/mid-size pharma and biotech companies worldwide, including GSK (UK), Wyeth (US), Servier (F), Intermune (US), Altana (D), Merck-Serono (D), Addex Therapeutics (CH), Hybrigenics (F), C10Pharma (NO), 4SC (D), 3V Biosciences (US), Polichem (CH), Crystax (E), Chiesi Farmaceutici (I), Dompè (I), Recordati (I), Newron Pharmaceuticals ( I), Teva (I).

He has a strong interest in teaching and training, and delivered hundreds of hours of seminars to students and professionals at several academic institutions and industrial locations.
He is a member of the Editorial Board of “Pharmaceutical Patent Analyst” (Future Science Group), co-inventor of 37 patent families and author of more than 100 presented works (54 scientific papers on peer-reviewed journals, 26 invited lectures/seminars to congresses and workshops, and 22 poster presentations).

Selected Publications

  • The antitussive activity of delta opioid receptor stimulation in guinea pigs. C.J. Kotzer, D.W.P. Hay, M. Dondio, G.A.M. Giardina, P. Petrillo, and D. Underwood. J. Pharmacol. Exp. Ther., 2000 292, 803-809.

  • The opioid- receptor-like 1 (ORL-1) as a potential target for new analgesics. D. Barlocco, G. Cignarella, G.A.M. Giardina and L. Toma. Eur. J. Med. Chem., 2000, 35, 275-282.

  • Recent advances on Neurokinin-3 (NK-3) receptor antagonists. G.A.M. Giardina, L. Raveglia and M. Grugni. Exp. Opin. Ther. Pat., 2000, 10(6), 939-960.

  • Moderni Criteri di Sviluppabilità del Farmaco. G.A.M. Giardina. Cronache Farmaceutiche, 2000, 2, 75-78.

  • Evidence that the proposed novel human “Neurokinin-4” receptor is pharmacologically similar to the human Neurokinin-3 receptor but is not of human origin. H.M. Sarau, J.L. Mooney, D.B. Schmidt, J.J. Foley, P.T. Buckley, G.A.M. Giardina, D.Y. Wang, J.A. Lee, D.W.P. Hay. Molecular Pharmacol., 2000, 58, 552-559.

  • Nonpeptide tachykinin receptor antagonists. II. Pharmacological and Pharmacokinetic profile of SB 222200, a CNS-penetrant, potent and selective NK-3 receptor antagonist. H.M. Sarau, D.E. Griswold, B. Bush, W. Potts, P. Sandhu, J.J. Foley, D.B. Schmidt, E.F. Webb, L.D. Martin, J.J. Legos, R.G. Whitmore, F.C. Barone, A.D. Medhurst,M.A. Luttmann,  G.A.M. Giardina and D.W.P. Hay. J. Pharmacol. Exp. Ther., 2000, 295, 373-381.

  • La Chimica combinatoria nel processo di drug discovery.  G.A.M. Giardina. Atti del Primo Laboratorio della SCI di Metodologie Sintetiche in Chimica Farmaceutica, Siena, Novembre 2001.

  • Lead generation and lead optimisation approaches in the discovery of selective, non-peptide ORL-1 receptor agonists and antagonists. G.A.M. Giardina, S. Ronzoni and I. Peretto. Exp. Opin. Ther. Pat., 2001, 11(4), 525-456.

  • Molecular and pharmacological characterization of the murine tachykinin NK-3 receptor. H.M. Sarau, J.A Field, R.S. Ames, J.J. Foley, P. Nuthulaganti, D.B. Schmidt, P.T. Buckley, N.A. Elshourbagy, M.E. Brawner, M.A. Luttmann, G.A.M. Giardina and D.W.P. Hay. Eur. J. Pharmacol. 2001, 413, 143-150.

  • Selective Delta Opioid Receptor Agonists for Inflammatory and Neuropathic Pain. G. Dondio, S. Ronzoni, C. Farina, P. Petrillo, C. Manzoni,  O. Angelici, G. Petrone, O. Pozzi, P. Zaratin,  S. Bingham,  M. A. Scheideler and G.A.M. Giardina. IL FARMACO, 2001, 56, 117-119.

  • Stepwise modulation of NK-3 and NK-2 receptor affinity and selectivity in quinoline tachykinin receptor antagonists. F. Blaney,L.F. Raveglia, M. Artico, S. Cavagnera, C. Dartois, C. Farina, M. Grugni, S. Gagliardi, M.A. Luttmann, M. Martinelli, G.M.M.G. Nadler, C. Parini, P. Petrillo, H.M. Sarau, M.A. Scheideler, D.W.P. Hay and G.A.M. Giardina. J. Med. Chem., 2001, 44(11), 1675-1689.

  • A new synthetic approach to 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-benzimidazol-2-one (J-113397), the first non-peptide ORL-1 receptor antagonist. C. De Risi,G.P. Pollini, C. Trapella, I. Peretto, S. Ronzoni and G.A.M. Giardina. Bioorg. & Med. Chem., 2001, 9, 1871-1877.

  • Industrie Chimiche in Italia: La “custom lead optimisation” arriva in Italia. G.A.M. Giardina. La Chimica e L’Industria, 2001, 83, 77-79.

  • Nonpeptide tachykinin receptor antagonists. III. SB 235375, a low CNS-penetrant, potent and selective NK-3 receptor antagonist, inhibits citric-acid-induced cough and airways hyperreactivity in guinea pigs. D.W.P. Hay, G.A.M. Giardina, D.E. Griswold, D. Underwood, C. Kotzer, B. Bush, W. Potts, P. Sandhu, D. Lundberg, J.J. Foley, D.B. Schmidt, L.D. Martin, D. Kilian, J.J. Legos, F.C. Barone, M.A. Luttmann, M. Grugni, L. Raveglia and H.M. Sarau. J. Pharmacol. Exp. Ther., 2002, 300, 314-323.

  • Dall’outsourcing della R&S: Le nuove opportunità di business nel settore farmaceutico. G.A.M. Giardina. Economia & Management, 2002, 4, 52.

  • Morphinan derivatives - A review of the recent patent literature. S. Gagliardi, G. Dondio and G.A.M. Giardina. IDrugs, 2003, 6(2), 129-137.

  • Antagonists at the neurokinin receptors - Recent patent literature. G.A.M. Giardina, S. Gagliardi and M. Martinelli. IDrugs, 2003, 6(8), 758-772.

  • Innovazioni nei processi di ricerca in campo farmaceutico. M. Muffatto e G.A.M. Giardina. Economia & Management, 2003, 6, 107-121.

  • Modification of nociception and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111).P.F. Zaratin, G. Petrone, M. Sbacchi, M. Garnier, C. Fossati, P. Petrillo, S. Ronzoni, G.A.M. Giardina, and M.A. Scheideler. J. Pharmacol. Exp. Ther., 2004, 308, 454-461.

  • Microwave-assisted highthroughput chemistry in lead generation and optimization. G.A.M. Giardina, M. Martinelli, A. Mortoni, N. Regalia and S. Gagliardi. Eds. P. Ettmayer, G. Ecker; Joint Meeting on Medicinal Chemistry, Proceedings Wien, June 20th-23rd 2005, pag. 117-122 - Publisher Monduzzi Editore, Bologna, Italy.

  • Discovery of diaryl imidazolidin-2-one derivatives, a novel class of muscarinic M3 selective antagonists (Part 1). Peretto, R. Forlani,C. Fossati, G.A.M. Giardina,A. Giardini, M. Guala, E. La Porta, P. Petrillo, S. Radaelli, L. Radice, L.F. Raveglia, E. Santoro, R. Scudellaro, F. Scarpitta, C. Bigogno, P. Misiano, G.M. Dondio, A. Rizzi, E. Armani, G. Amari, M. Civelli, G. Villetti, R. Patacchini, M. Bergamaschi, M. Delcanale, C. Salcedo, A.G. Fernández and B.P. Imbimbo. J. Med. Chem., 2007, 50, 1571-1583.

  • Discovery of Diaryl Imidazolidin-2-one Derivatives, a Novel Class of Muscarinic M3 Selective Antagonists (Part 2). Peretto,C. Fossati, G.A.M. Giardina, A. Giardini M. Guala, E. La Porta, P. Petrillo, S. Radaelli, L. Radice, L.F. Raveglia, E. Santoro, R. Scudellaro, F. Scarpitta, A. Cerri,  S. Menegon, G.M. Dondio, A. Rizzi, E. Armani, G. Amari, M. Civelli, G. Villetti, R. Patacchini, M. Bergamaschi, Franco Bassani, M. Delcanale and B.P. Imbimbo. J. Med. Chem., 2007, 50, 1693-1697.

  • Creating effective medicinal chemistry collaborations in drug discovery. G.A.M. Giardina, L.F. Raveglia. Future Med. Chem., 2009, 1(1), 3-6.

  • Accelerating the Drug Discovery Process: New Tools and Technologies Available to Medicinal Chemists. L.F. Raveglia, G.A.M. Giardina. Future Med. Chem., 2009, 1(6), 1019-1023.

  • γ-Secretase Inhibitors and Modulators for the Treatment of Alzheimer’s Disease: Disappointments and Hopes. B.P Imbimbo and G.A.M. Giardina. Commemorative annual issue, Editor: Allen.B. Reitz. Curr. Topics Med. Chem., 2011, 11(12), 1555-1570.

  • Ask the experts: IP issues  facing researchers. Interview by Pharmaceutical Patent Analyst. , O. Almarsson, M. Angiolini, J. Baell, G. Giardina, A. Ingham, A. Hughes, P. Pevarello, R. Sindelar. Pharmaceutical Patent Analyst, 2012, 1(2), 129-135.


IIT's website uses the following types of cookies: browsing/session, analytics, functional and third party cookies. Users can choose whether or not to accept the use of cookies and access the website. By clicking on "Further Information", the full information notice on the types of cookies will be displayed and you will be able to choose whether or not to accept them whilst browsing on the website
Further Information
Accept and close

I numeri di IIT

L’Istituto Italiano di Tecnologia (IIT) è una fondazione di diritto privato - cfr. determinazione Corte dei Conti 23/2015 “IIT è una fondazione da inquadrare fra gli organismi di diritto pubblico con la scelta di un modello di organizzazione di diritto privato per rispondere all’esigenza di assicurare procedure più snelle nella selezione non solo nell’ambito nazionale dei collaboratori, scienziati e ricercatori ”.

IIT è sotto la vigilanza del Ministero dell'Istruzione, dell'Università e della Ricerca e del Ministero dell'Economia e delle Finanze ed è stato istituito con la Legge 326/2003. La Fondazione ha l'obiettivo di promuovere l'eccellenza nella ricerca di base e in quella applicata e di favorire lo sviluppo del sistema economico nazionale. La costruzione dei laboratori iniziata nel 2006 si è conclusa nel 2009.

Lo staff complessivo di IIT conta circa 1440 persone. L’area scientifica è rappresentata da circa l’85% del personale. Il 45% dei ricercatori proviene dall’estero: di questi, il 29% è costituito da stranieri provenienti da oltre 50 Paesi e il 16% da italiani rientrati. Oggi il personale scientifico è composto da circa 60 principal investigators, circa 110 ricercatori e tecnologi di staff, circa 350 post doc, circa 500 studenti di dottorato e borsisti, circa 130 tecnici. Oltre 330 posti su 1400 creati su fondi esterni. Età media 34 anni. 41% donne / 59 % uomini.

Nel 2015 IIT ha ricevuto finanziamenti pubblici per circa 96 milioni di euro (80% del budget), conseguendo fondi esterni per 22 milioni di euro (20% budget) provenienti da 18 progetti europei17 finanziamenti da istituzioni nazionali e internazionali, circa 60 progetti industriali

La produzione di IIT ad oggi vanta circa 6990 pubblicazioni, oltre 130 finanziamenti Europei e 11 ERC, più di 350 domande di brevetto attive, oltre 12 start up costituite e altrettante in fase di lancio. Dal 2009 l’attività scientifica è stata ulteriormente rafforzata con la creazione di dieci centri di ricerca nel territorio nazionale (a Torino, Milano, Trento, Parma, Roma, Pisa, Napoli, Lecce, Ferrara) e internazionale (MIT ed Harvard negli USA) che, unitamente al Laboratorio Centrale di Genova, sviluppano i programmi di ricerca del piano scientifico 2015-2017.

IIT: the numbers

Istituto Italiano di Tecnologia (IIT) is a public research institute that adopts the organizational model of a private law foundation. IIT is overseen by Ministero dell'Istruzione, dell'Università e della Ricerca and Ministero dell'Economia e delle Finanze (the Italian Ministries of Education, Economy and Finance).  The Institute was set up according to Italian law 326/2003 with the objective of promoting excellence in basic and applied research andfostering Italy’s economic development. Construction of the Laboratories started in 2006 and finished in 2009.

IIT has an overall staff of about 1,440 people. The scientific staff covers about 85% of the total. Out of 45% of researchers coming from abroad 29% are foreigners coming from more than 50 countries and 16% are returned Italians. The scientific staff currently consists of approximately 60 Principal Investigators110 researchers and technologists350 post-docs and 500 PhD students and grant holders and 130 technicians. External funding has allowed the creation of more than 330 positions . The average age is 34 and the gender balance proportion  is 41% female against 59% male.

In 2015 IIT received 96 million euros in public funding (accounting for 80% of its budget) and obtained 22 million euros in external funding (accounting for 20% of its budget). External funding comes from 18 European Projects, other 17 national and international competitive projects and approximately 60 industrial projects.

So far IIT accounts for: about 6990 publications, more than 130 European grants and 11 ERC grants, more than 350 patents or patent applications12 up start-ups and as many  which are about to be launched. The Institute’s scientific activity has been further strengthened since 2009 with the establishment of 11 research nodes throughout Italy (Torino, Milano, Trento, Parma, Roma, Pisa, Napoli, Lecce, Ferrara) and abroad (MIT and Harvard University, USA), which, along with the Genoa-based Central Lab, implement the research programs included in the 2015-2017 Strategic Plan.